In total, consumption of SGLT2 (sodium/glucose cotransporter 2) inhibitors increased heavily from 144,018 DDDs in 2016 to 245,228 DDDs in 2017 whereas consumption of other diabetes medications decreased during the same period (Additional file 2). Here, SLC5A2 is linked to diabetes mellitus.